1. Neuro-oncologists have spoken – the role of bevacizumab in the inpatient setting. A clinical and economic conundrum
   Akanksha Sharma et al, 2019, Neuro-Oncology Practice CrossRef
2. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial
   Mei Zhan et al, 2017, Lung Cancer CrossRef
3. Bevacizumab: Is the lower the better for glioblastoma patients in progression?
   Lila Sirven-Villaros et al, 2018, Bulletin du Cancer CrossRef
4. Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment
   Nicholas J. Goel et al, 2021, Journal of Medical Economics CrossRef
5. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis
   null null et al, 2021, Cochrane Database of Systematic Reviews CrossRef
6. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
   Minjie Fu et al, 2023, BMC Cancer CrossRef
7. Effect of health disparities on overall survival of patients with glioblastoma
   Jacob J. Mandel et al, 2019, Journal of Neuro-Oncology CrossRef